David H. Mack, Ph.D.

David H. Mack, Ph.D.

President, Chief Executive Officer and DirectoratPMV Pharmaceuticals· In proxies 2022–2025

Pay in FY2025-65% from the year before · PMV Pharmaceuticals stock -17.2% the same year

David H. Mack, Ph.D. was paid $1.7M in FY2025 (Dec), down 65%. PMV Pharmaceuticals stock fell 17.2% that year.

Pay$100 in the stock at the end of FY21 → $5
Pay is from the Summary Compensation Table of each PMV Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. PMV PharmaceuticalsPublic company · 4 yr
    • President, Chief Executive Officer and Director2022 – Present · 4 yrStock in role -94%

Roles come from the proxy statements of each company.

Boards1

  • PMV PharmaceuticalsDirector · 12 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?